Palliative Care in Gynecologic Oncology.

Obstet Gynecol Clin North Am

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, Alvin J. Siteman Cancer Center, 660 South Euclid Avenue, Mail Stop 8064-37-905, St Louis, MO 63110, USA. Electronic address:

Published: March 2019

The integration of palliative care and hospice into standard gynecologic oncology care is associated with cost-savings, longer survival, lower symptom burden, and better quality of life for patients and caregivers. Consequently, this comprehensive approach is formally recognized and endorsed by the Society of Gynecologic Oncology, the National Comprehensive Cancer Network, and the American Society of Clinical Oncology. This article reviews the background, benefits, barriers, and most practical delivery models of palliative care. It also discusses management of common symptoms experienced by gynecologic oncology patients.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ogc.2018.10.001DOI Listing

Publication Analysis

Top Keywords

gynecologic oncology
16
palliative care
12
oncology
5
gynecologic
4
care gynecologic
4
oncology integration
4
integration palliative
4
care hospice
4
hospice standard
4
standard gynecologic
4

Similar Publications

Introductory Analysis and Validation of CUT&RUN Sequencing Data.

J Vis Exp

December 2024

Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center; Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center;

The CUT&RUN technique facilitates detection of protein-DNA interactions across the genome. Typical applications of CUT&RUN include profiling changes in histone tail modifications or mapping transcription factor chromatin occupancy. Widespread adoption of CUT&RUN is driven, in part, by technical advantages over conventional ChIP-seq that include lower cell input requirements, lower sequencing depth requirements, and increased sensitivity with reduced background signal due to a lack of cross-linking agents that otherwise mask antibody epitopes.

View Article and Find Full Text PDF

Unveiling sialoglycans' immune mastery in pregnancy and their intersection with tumor biology.

Front Immunol

January 2025

Medical Genetic Institute of Henan Province, Henan Key Laboratory of Genetic Diseases and Functional Genomics, National Health Commission Key Laboratory of Birth Defects Prevention, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.

Sialylation is a typical final step of glycosylation, which is a prevalent post-translational modification of proteins. Sialoglycans, the products of sialylation, are located on the outmost of cells and participate in pivotal biological processes. They have been identified as glyco-immune checkpoints and are currently under rigorous investigation in the field of tumor research.

View Article and Find Full Text PDF

Cervical cancer (CC), which ranks among the four most common cancers in women, is a leading cause of both illness and death globally. It's urgent to identify a new biomarker to elucidate the potential mechanisms underlying the progression of CC. Here, we screened the differentially expressed genes (DEGs) in the Cancer Genome Atlas database (TCGA) and selected Chromosome 1 open reading frame 74 (C1orf74) for further investigation.

View Article and Find Full Text PDF

Objective: There is no standard clinical trial screening process in gynecologic oncology. In our low resource, highly diverse gynecologic oncology patient population, we sought to create an equitable, adaptable, manual screening process.

Methods: Our objective is to describe our clinical trial screening process and success in improving trial enrollment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!